Alseres raises $200K in private financing
The USA's Alseres Pharmaceuticals has entered into a securities purchase agreement with Cato Holding Co for the private placement of 200,000 shares of its common stock of the firm at a purchase price of $1.00 per share.
The financing resulted in total gross proceeds of $200,000, which the firm intends to use to satisfy certain amounts owed to Cato Research, a contract research organization and a related party to Cato BioVentures.
The securities offered and sold by Alseres in this private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the USA absent registration with the Securities and Exchange Commission or an applicable exemption from registration requirements.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze